The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cemiplimab as first intervention for patients with locally advanced cutaneous squamous cell carcinoma.
 
Jennifer Lynn Atlas
Research Funding - Bristol-Myers Squibb (Inst); Regeneron (Inst)
 
Marina Kanos
Consulting or Advisory Role - Exelixis
 
James Thomas Symanowski
Consulting or Advisory Role - Boston Biomedical; CARsgen Therapeutics; Endocyte (Inst); Five Prime Therapeutics; Immatics; Lilly
 
Daniel Brickman
No Relationships to Disclose
 
Meghan Forster
No Relationships to Disclose
 
Catherine Frenkel
No Relationships to Disclose
 
Zvonimir Milas
No Relationships to Disclose
 
Terry Sarantou
No Relationships to Disclose
 
Richard L. White
No Relationships to Disclose
 
Asim Amin
Consulting or Advisory Role - Merck; Novartis
Speakers' Bureau - Bioarray Therapeutics; Bristol-Myers Squibb; Exelixis; Merck; Novartis; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Merck (Inst)